Plasma Protein Binding in Drug Discovery and Development

被引:116
作者
Howard, Monique L. [1 ]
Hill, John J. [1 ]
Galluppi, Gerald R. [2 ]
McLean, Matthew A. [1 ]
机构
[1] Amgen Inc, Seattle, WA 98119 USA
[2] Biogen Idec Inc, San Diego, CA 92122 USA
关键词
Plasma protein binding; human serum albumin; pharmacokinetics; equilibrium dialysis; ultrafiltration; ultracentrifugation; optical biosensors and micropartitioning; HUMAN-SERUM-ALBUMIN; SOLID-PHASE MICROEXTRACTION; TANDEM MASS-SPECTROMETRY; HUMAN ALPHA(1)-ACID GLYCOPROTEIN; SEDIMENTATION-VELOCITY ANALYSIS; COEFFICIENT DISTRIBUTIONS C(S); FATTY-ACID CONCENTRATION; EQUILIBRIUM-DIALYSIS; LIQUID-CHROMATOGRAPHY; ALPHA-1-ACID GLYCOPROTEIN;
D O I
10.2174/138620710790596745
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This review describes methods for quantifying the binding of small molecule drug candidates to plasma proteins and the application of these methods in drug discovery and development. Particular attention is devoted to methods amenable to medium-to-high throughput analysis and those well suited for measurement of compounds that are highly protein bound. The methods reviewed herein include the conventional techniques of equilibrium dialysis, ultrafiltration and ultracentrifugation, as well as some more novel approaches utilizing micropartitioning and biosensor-based analysis. Additional concepts that are discussed include plasma protein structure, enantioselective protein binding, drug displacement, the effect of patient demographics and disease states on free (unbound) drug levels, and the influence of protein binding on drug candidate pharmacokinetics and pharmacodynamics. Practical considerations pertaining to the evaluation of highly protein bound drug candidates are also highlighted.
引用
收藏
页码:170 / 187
页数:18
相关论文
共 188 条
[1]   Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor [J].
Acharya, MR ;
Sparreboom, A ;
Sausville, EA ;
Conley, BA ;
Doroshow, JH ;
Venitz, J ;
Figg, WD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (03) :275-281
[2]   Determination of fraction unbound docetaxel using microequilibrium dialysis [J].
Acharya, MR ;
Baker, SD ;
Verweij, J ;
Figg, WD ;
Sparreboom, A .
ANALYTICAL BIOCHEMISTRY, 2004, 331 (01) :192-194
[3]   Use of surface plasmon resonance biosensor technology as a possible alternative to detect differences in binding of enantiomeric drug compounds to immobilized albumins [J].
Ahmad, A ;
Ramakrishnan, A ;
McLean, MA ;
Breau, AP .
BIOSENSORS & BIOELECTRONICS, 2003, 18 (04) :399-404
[4]   FREE FRACTION OF VALPROIC ACID - INVITRO TIME-DEPENDENT INCREASE AND CORRELATION WITH FREE FATTY-ACID CONCENTRATION IN HUMAN-PLASMA AND SERUM [J].
ALBANI, F ;
RIVA, R ;
PROCACCIANTI, G ;
BARUZZI, A ;
PERUCCA, E .
EPILEPSIA, 1983, 24 (01) :65-73
[5]  
[Anonymous], 1980, Biophysical Chemistry: Part III: The Behavior of Biological Macromolecules
[6]  
[Anonymous], CHROMATOGRAPHY
[7]   Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake [J].
Baker, M. ;
Parton, T. .
XENOBIOTICA, 2007, 37 (10-11) :1110-1134
[8]   Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding [J].
Banker, MJ ;
Clark, TH ;
Williams, JA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) :967-974
[9]   Determination of free levels of phenytoin in human plasma by liquid chromatography/tandem mass spectrometry [J].
Bardin, S ;
Ottinger, JC ;
Breau, AP ;
O'Shea, TJ .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (2-3) :573-579
[10]   Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration [J].
Barrail, A ;
Le Tiec, C ;
Paci-Bonaventure, S ;
Furlan, V ;
Vincent, I ;
Taburet, AM .
THERAPEUTIC DRUG MONITORING, 2006, 28 (01) :89-94